GENinCode secures £4 million in new funding round

Published 14/02/2025, 11:04
GENinCode secures £4 million in new funding round

LONDON - GENinCode PLC (AIM: GENI), a company specializing in predictive genetics for the prevention of cardiovascular disease, has successfully raised £4 million before expenses through a share placement and subscription. The funding round issued 108,108,108 new ordinary shares at a price of 3.7 pence each, which is a 5.1% discount to the closing market price of the company's shares on February 13, 2025.

The placement was managed through an accelerated bookbuild process by Cavendish and Oberon, who acted as agents on behalf of GENinCode. The fundraising is part of a broader strategy that also included a retail offer, details of which will be announced on February 18, 2025.

Directors of the company also participated in the subscription, with some, including Jordi Puig, Matthew Walls, Sergio Olivero, Paul Foulger, and Huon Gray, investing through affiliated parties. The share allocations to the directors are part of the overall issuance and will be finalized upon successful admission of the new shares to trading on the AIM market of the London Stock Exchange (LON:LSEG), expected around March 4, 2025.

The fundraising and share issuance are contingent upon the approval of shareholders at the General Meeting scheduled for March 3, 2025. A circular detailing the fundraising and the resolutions required for implementation will be made available to shareholders and posted on the company's investor relations website.

Following the admission of the new shares and assuming full participation in the retail offer, GENinCode's issued share capital will increase to 298,586,048 ordinary shares. These shares will rank equally with existing shares, granting holders the same rights to dividends and distributions.

This news is based on a press release statement and is intended for informational purposes only. It provides an overview of GENinCode's recent financing activities and outlines the involvement of company directors in the subscription process. The company's share price and the discount offered in the placement reflect the market conditions as of the last business day before the announcement of the fundraising.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.